![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: John Wiley & Sons Inc
E-ISSN: 2160-7648|2|4|316-327
ISSN: 2160-763X
Source: Clinical Pharmacology In Drug Development, Vol.2, Iss.4, 2013-10, pp. : 316-327
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Hepatitis C NS3 protease inhibitors
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 5, 1999-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel tripeptide inhibitors of hepatitis C virus NS3 serine protease
Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 6, Iss. 1, 2006-03 ,pp. :